Jacobi Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Jacobi Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9	Closed	-$5K	–	539
2021 Q3	$5K	Hold	9	–	–	﹤0.01%	1185
2021 Q2	$4K	Hold	9	–	–	﹤0.01%	1182
2021 Q1	$6K	Hold	9	–	–	﹤0.01%	1071
2020 Q4	$7K	Hold	9	–	–	﹤0.01%	931
2020 Q3	$7K	Hold	9	–	–	﹤0.01%	867
2020 Q2	$8K	Hold	9	–	–	﹤0.01%	811
2020 Q1	$3K	Buy	+9	New	+$3.23K	﹤0.01%	894

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jacobi Capital Management's BTAI Position: Q4 2021 in Review

Jacobi Capital Management sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 9 shares — an estimated $5K sold.

Jacobi Capital Management first reported a position in BTAI in Q1 2020 and held it in 7 quarters. The position peaked at $8K in Q2 2020. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

Jacobi Capital Management reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
Jacobi Capital Management sold 9 BioXcel Therapeutics shares in Q4 2021, an estimated $5K.
Jacobi Capital Management first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 7 quarters.
Jacobi Capital Management's BioXcel Therapeutics position peaked at $8K in Q2 2020.
93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.